| 8.44 0.08 (0.96%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.8  |
1-year : | 11.56 |
| Resists | First : | 9.25 |
Second : | 9.89 |
| Pivot price | 9.21 |
|||
| Supports | First : | 8.21 | Second : | 6.83 |
| MAs | MA(5) : | 8.81 |
MA(20) : | 9.31 |
| MA(100) : | 9.72 |
MA(250) : | 8.51 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 17.4 |
| RSI | RSI(14): 28.1  |
|||
| 52-week | High : | 11.14 | Low : | 6.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRFS ] has closed above bottom band by 0.1%. Bollinger Bands are 60.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.47 - 8.52 | 8.52 - 8.57 |
| Low: | 8.11 - 8.17 | 8.17 - 8.23 |
| Close: | 8.35 - 8.44 | 8.44 - 8.52 |
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Sun, 09 Nov 2025
Grifols (NASDAQ:GRFS) Cut to "Hold" at Zacks Research - MarketBeat
Sun, 09 Nov 2025
Credit Industriel ET Commercial Sells 99,100 Shares of Grifols, S.A. $GRFS - MarketBeat
Thu, 06 Nov 2025
Down 10.4% in 4 Weeks, Here's Why Grifols (GRFS) Looks Ripe for a Turnaround - Yahoo Finance
Thu, 06 Nov 2025
Grifols, S.A. (NASDAQ:GRFS) Q3 2025 Earnings Call Transcript - Insider Monkey
Wed, 05 Nov 2025
Grifols SA Reports Strong Q3 Earnings Amid Challenges - TipRanks
Tue, 04 Nov 2025
Grifols SA Reports Strong Q3 2025 Financial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 258 (M) |
| Shares Float | 535 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 58 (%) |
| Shares Short | 5,920 (K) |
| Shares Short P.Month | 5,350 (K) |
| EPS | 0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.59 |
| Profit Margin | 3.9 % |
| Operating Margin | 18.4 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 4.9 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 11.54 |
| Sales Per Share | 28.85 |
| EBITDA (p.s.) | 6.73 |
| Qtrly Earnings Growth | 750 % |
| Operating Cash Flow | 1,100 (M) |
| Levered Free Cash Flow | 718 (M) |
| PE Ratio | 16.54 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 0.29 |
| Price to Cash Flow | 1.98 |
| Dividend | 0.17 |
| Forward Dividend | 0 |
| Dividend Yield | 2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|